Presented by

NEWS
Short Week Strikes Again

Happy Friday Thursday. Despite a daily climb, the market fell over the past week— three out of four shortened weeks have been red in 2025. Sounds like the makings of a strategy. 🚗 

Earnings results pulled the indexes in different directions today, with bad UNH results sending the Dow lower, a rare divergence from the climbing S&P 500. Netflix earnings beat estimates, reminding everyone that there are companies outside tariff agreements.

President Trump said today he could fire Fed Chair Jerome Powell if he wanted to, and the WSJ reported sources said he has worked on the project for weeks. 👀

Today’s issue covers Netflix beating, UnitedHealth missing, Eli Lilly cutting weight, and more. 📰

Here’s the S&P 500 heatmap. 9 of 11 sectors closed green, with energy (+1.8%) leading and health care (-0.8%) lagging.

Source: finviz

And here are the closing prices: 

STOCKS
Netflix Beyond Borders 🐻 

Investors gleefully waited for the first major tech firms outside the Mag 7 to report today, hoping that Netflix’s streaming service could have the right stuff to avoid any tariff mayhem.

Netflix reported an eps of $6.61/share on revenue of $10.54B for Q1, above estimates. The firm made no changes to its 2025 guidance, but said a price increase last year helped boost its first-quarter profit. 🫰 

It was the first quarter the streaming firm reported without mentioning its global subscriber numbers, a measure it had wanted to avoid. Bloomberg consensus estimates were looking for revenue of $10.50 billion versus $9.37 billion last year and EPS of $5.68 versus $5.28

In January, the firm raised its 2025 revenue guidance to $43.5 billion to $44.5 billion.

Beating estimates, the stock climbed 4% after hours, following a 6% increase this week after The Wall Street Journal reported that management was aiming for a $1 trillion valuation by 2030. Stocktwits user sentiment was off the charts on this one. 🥵 

Source: Stocktwits

SPONSORED
What If You’d Bought Apple in 2007 Instead of the iPhone?

In 2007, the first iPhone launched at $599 – too pricey for most.

But Apple stock? Just $17 per share.

If you’d invested that same $599 in Apple stock instead of the phone, it would be worth over $167,000 today.

You didn’t need to buy the product. You just needed to see the shift.

Pacaso is doing the same for luxury real estate. Co-founded by Zillow’s CEO, Spencer Rascoff, Pacaso lets people co-own second homes – and gives investors access to the upside behind it.

• $1B+ in transactions

• $100M+ in gross profit

• Revenue on every sale and resale

• Backed by SoftBank, Greycroft, and GFC.

Pacaso is a private company and you have the chance to become an investor.

Own a stake in the next platform shift. Invest Today.

*3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here. This is a paid advertisement for Pacaso’s Regulation A offering. Please read the offering circular at invest.pacaso.com. There’s no guarantee that Pacaso will file for an IPO.

COMPANY NEWS
UnitedHealth Hurts The Dow, While Lilly Pops Pills 🫠 

UnitedHealth reported its first earnings miss in over a decade on Thursday morning, causing the entire Dow to fall as the stock dropped 23%.

The firm slashed projections for 2025, citing problems in its Medicare business, which pulled down the health insurance industry. Humana and CVS were down by more than 6%. The firm was nine cents off with an EPS of $7.20, and cut full year numbers by about $4 to $30 per share. 🍴 

The issue? Way more people were using its Medicare plans, and enrollees were getting more checkups, which cost the firm more money than anticipated.

The Wall Street Journal reported the firm made the mistake of helping too many sick people by picking up new clients who had previously undocumented illnesses.

Not all healthcare went red- the other side of the S&P 500 Thursday was a 16% climb in Eli Lilly after the firm said their weight loss pill passed a phase 3 trial on Type 2 diabetes patients.

The experimental pill orforglipron is the first oral GLP-1 receptor agonist to complete phase 3. If the drug hits the open market, it will compete directly with injection weight loss drugs like Novo Nordisk’s Ozempic.

Stocktwits users are extremely bullish on the stock. 🌶️ 

Source: Stocktwits

Like injectable GLP-1, the study brought significant weight loss, with up to 7% of body weight, or 16 lbs, off the highest dose. Also, like other GLP-1s, the drug has the side effect of upsetting users’ stomachs.

Patients will have to weigh shrinking tummies against tummy aches, and based on Novo Nordisk’s sales numbers, they will likely choose thin and rumbly.🫃 

STOCKS
Other Noteworthy Pops & Drops 📋️ 

Taiwan Semiconductor ($TSM): The world’s largest contract chipmaker reaffirmed a bullish outlook for the year, citing strong demand for AI chips and stable customer behavior despite U.S. tariff uncertainties. It was not enough to pull up the rest of the industry by the day’s end.

Charles Schwab ($SCHW +0.6%): Shares of brokerage giant Schwab rallied after first-quarter earnings surpassed Wall Street expectations, with an EPS of $1.04. Revenue surged over 18% YoY to $5.6 billion, exceeding the $5.53 billion forecast.

American Express ($AXP -0.6%): Credit leader Amex posted quarter earnings, but the stock fell in the afternoon. Total revenue increased 7% YoY to $16.97 billion, driven by higher net interest income, card member spending, and fee growth.

Blackstone ($BX +0.8%): Q1 earnings and revenue declined year-over-year at private credit firm Blackstone, but still exceeded Wall Street estimates. Total AUM rose 10% YoY to $1.17 trillion, with inflows of $61.6 billion during the quarter.

Nvidia ($NVDA -3%): CEO Jensen Huang visited Beijing amid escalating U.S.-China trade tensions. According to CCTV, Huang emphasized the significance of the Chinese market for Nvidia and expressed hope for continued cooperation.

Lockheed Martin ($LMT -2%): Shares dropped over 4% at the missile maker after it announced that CFO Jesus ‘Jay’ Malave is stepping down after 26 years.

Temu Owner PinDuoDuo ($PDD +1.5%): The Chinese e-commerce platforms Temu and Sein announced plans to raise product prices next week following the U.S. government’s 245% tariff hike on Chinese goods. Both companies urged shoppers to buy at current rates before the price increase takes effect on April 25.

Gold ETF (GLD -0.4%): Gold/USD hit a record $3,357 an ounce on Thursday before settling at $3,300. The safe-haven commodity has surged nearly 28% year-to-date.

Channel Therapeutics ($CHRO +47%): Shares of the NJ-based biotech firm soared following a definitive merger agreement with Ligand Pharmaceuticals ($LGND).

IN PARTNERSHIP WITH MONEYSHOW
Retail Sentiment’s Read On This Market 🤔 

Stocktwits’ Editor-In-Chief, Tom Bruni, joins MoneyShow’s Mike Larson to discuss what Stocktwits data currently shows about the active retail investor and trader.

• What’s driving record levels of uncertainty

• Where the attention is flowing right now

• How retail is thinking about alternatives like gold and Bitcoin

• What to expect at the Stocktwits Cashtag Awards on April 30

If you’re in the New York area and are interested in attending The Cashtag Awards, reply directly to this email with the words “I’m In.” Tickets are limited, but we’ll do our best to hook our loyal newsletter readers up so we can see you there!

Want to guarantee you can attend? Grab your tickets now! 🎫 

Links That Don’t Suck 🌐

🌞 Ready to grow your portfolio? Spring into action with help from IBD Digital and save $65+*

🩸 The CFPB has been gutted

🥧 Bill Ackman makes big bet on Hertz becoming tariff winner

🥸 Apple Vision ‘Air’ will use titanium to cut weight and come in black, per leak

🏚️ Homebuyers rush to riskier loans, as tariff turmoil pushes interest rates higher

📸 Instagram’s new Blend feature creates a custom reels feed for you and your friends

😅 Trump Has for Months Privately Discussed Firing Fed Chair Powell

*3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here.

Get In Touch 📬

Follow our social channels for great, real-time content on Stocktwits and Twitter. And check out our YouTube channel for in-depth video content! 📲

Help us deliver the best content possible by completing this brief survey. 📝

Email me (Kevin Travers) your feedback; follow me on Stocktwits. I’d love to hear from you. 📧

Want to sponsor this newsletter and reach hundreds of thousands of passionate investors and traders? Reach us here. 

Terms & Conditions 📝

Securities Disclaimer: STOCKTWITS IS NOT A TAX ADVISOR, BROKER, FINANCIAL ADVISOR OR INVESTMENT ADVISOR. THE SERVICE IS NOT INTENDED TO PROVIDE TAX, LEGAL, FINANCIAL OR INVESTMENT ADVICE, AND NOTHING ON THE SERVICE SHOULD BE CONSTRUED AS AN OFFER TO SELL, A SOLICITATION OF AN OFFER TO BUY, OR A RECOMMENDATION FOR ANY SECURITY. Trading in such securities can result in immediate and substantial losses of the capital invested. You should only invest risk capital, and not capital required for other purposes. You alone are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should also consult an attorney or tax professional regarding your specific legal or tax situation. The Content is to be used for informational and entertainment purposes only and the Service does not provide investment advice for any individual. Stocktwits, its affiliates and partners specifically disclaim any and all liability or loss arising out of any action taken in reliance on Content, including but not limited to market value or other loss on the sale or purchase of any company, property, product, service, security, instrument, or any other matter. You understand that an investment in any security is subject to a number of risks, and that discussions of any security published on the Service will not contain a list or description of relevant risk factors. In addition, please note that some of the stocks about which Content is published on the Service have a low market capitalization and/or insufficient public float. Such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information. Read the full terms & conditions here. 🔍

Author Disclosure: The author of this newsletter does not hold positions in any of the securities or assets mentioned. 📋